Stockscreener 앱 받기
72.73
2.28%
-1.70
시간 외 거래:
72.73
Haemonetics Corp 주식(HAE)의 최신 뉴스
HAE Maintained by Mizuho -- Price Target Raised to $85.00 - GuruFocus
Mizuho raises Haemonetics stock price target to $85 on plasma demand - Investing.com UK
HAE SEC FilingsHaemonetics Corp Mass 10-K, 10-Q, 8-K Forms - Stock Titan
Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices? - simplywall.st
HAEMONETICS CORP ($HAE) President and CEO 2026 Pay Revealed - Quiver Quantitative
[ARS] HAEMONETICS CORP SEC Filing - Stock Titan
Executive pay and equity plans in Haemonetics (NYSE: HAE) 2026 proxy filing - Stock Titan
A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment - Yahoo Finance
A Look at Haemonetics Corp (HAE) After 5.0% Gain -- GF Value $84 - GuruFocus
Haemonetics (NYSE: HAE) VP settles RSU taxes with 259 withheld shares - Stock Titan
Haemonetics (HAE) SVP has 313 shares withheld for RSU tax obligations - Stock Titan
Haemonetics Corp at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Haemonetics Corp stock (US4041191090): solid growth story in blood management and plasma technology - AD HOC NEWS
Is Haemonetics (HAE) Stock Price Reflecting Its Recent 29% Monthly Surge Accurately - simplywall.st
Haemonetics Corp stock (US4041191090): segment restructuring shifts focus to Apheresis and MedSurg - AD HOC NEWS
Haemonetics Restructures Business Segments for Enhanced Efficien - GuruFocus
Haemonetics Updates Financial Reporting Segments, Combines Plasma and Blood Center Into Apheresis, Renames Hospital to MedSurg 1 - Minichart
Haemonetics restructures reporting segments from three to two - Investing.com
Haemonetics updates reporting structure, combines Plasma and Blood Center into Apheresis - TradingView
Haemonetics (NYSE: HAE) consolidates business into new Apheresis and MedSurg segments - Stock Titan
Haemonetics Updates Financial Reporting Segments - PR Newswire
Haemonetics Corp (HAE) Shares Surge 6.0% -- What GF Score of 79 Tells Investors - GuruFocus
Haemonetics earnings ahead: Can vascular closure rebound? - Investing.com
Haemonetics stock falls from recent highs amid weekly seller pressure and overbought signals - Traders Union
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference - PR Newswire
Haemonetics Corp stock (US4041191090): shares trade lower after recent pullback on NYSE - AD HOC NEWS
HAE Maintained by Citigroup -- Price Target Raised to $70 - GuruFocus
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Raises Target Price to $70 - 富途牛牛
Why Haemonetics NYSE Composite Earnings Sparked Attention? - Kalkine Media
Haemonetics' (NYSE:HAE) Conservative Accounting Might Explain Soft Earnings - simplywall.st
Why Haemonetics (HAE) Is Up 14.3% After Earnings Beat And BofA Upgrade And What's Next - Yahoo Finance
Is It Time To Reassess Haemonetics (HAE) After The Recent Share Price Jump - simplywall.st
Haemonetics (HAE) Stock Is Up, What You Need To Know - Yahoo Finance
Medical Devices & SuppliesSpecialty Stocks Q1 Highlights: Haemonetics (NYSE:HAE) - Yahoo Finance
Haemonetics (HAE) Upgraded to Buy by Bank of America, Target Pri - GuruFocus
HAE Upgraded by B of A Securities -- Price Target Raised to $80 - GuruFocus
Haemonetics (HAE) Upgraded to Buy by Bank of America, Shares Cli - GuruFocus
Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends - Yahoo! Finance Canada
This Texas Instruments Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday - Benzinga
BofA upgrades Haemonetics stock rating on conservative guidance - Investing.com
BofA upgrades Haemonetics stock rating on conservative guidance By Investing.com - Investing.com Canada
Is It Too Late to Buy Haemonetics Corp (HAE) After 4.0% Rally? G - GuruFocus
Does Haemonetics (HAE) Have Enduring Growth Potential? - Insider Monkey
Q3 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Haemonetics Corp 2026 Annual Report: Business Overview, Market Segments, Products, and Competitive Landscape - Minichart
Haemonetics (NYSE: HAE) outlines segment shifts, major customers and risks - Stock Titan
Haemonetics (HAE) EVP and General Counsel receives 28,424 RSUs, 2,913 shares withheld for taxes - Stock Titan
[Form 4] HAEMONETICS CORP Insider Trading Activity - Stock Titan
Haemonetics (NYSE: HAE) CFO granted 29,312 RSUs with tax withholding - Stock Titan
Haemonetics (NYSE: HAE) VP granted 2,220 RSUs, 197 shares withheld for tax - Stock Titan
Haemonetics (HAE) EVP Roy Galvin granted RSUs as 879 shares withheld for taxes - Stock Titan
Haemonetics (HAE) SVP granted RSUs while shares withheld to cover taxes - Stock Titan
Haemonetics (HAE) CEO receives 78,344 RSUs and has shares withheld for taxes - Stock Titan
Does Haemonetics' (HAE) Buyback-Funded Loss Quarter Hint at Shifting Earnings Quality Priorities? - simplywall.st
Haemonetics (HAE) Valuation Check As Earnings Pressure And Options Volatility Raise Questions - simplywall.st
2.43%
자본화:
|
볼륨(24시간):